by Tina Young and Robin Douglas
Volume 2, Issue 3 (May/June 2003)
Long-term growth of the biopharmaceutical industry is increasingly relying on outsourcing to overcome the current capacity constraints, especially for monoclonal antibody production. Companies are often reluctant to commit to building multimillion dollar manufacturing facilities for potential products with no guarantee of approval. Therefore to offset risks, companies will enter into contract manufacturing arrangements…
Citation:
Young T, Douglas R. Managing Raw Materials in a Contract Manufacturing Facility. BioProcess J, 2003; 2(3): 47-49.